Speeding up COVID-19 PCR-test diagnostics
(PresseBox) - The SARS-CoV-2 virus global outbreak generated a need for fast and reliable large-scale testing to diagnose and prevent further COVID-19 transmission. One of the main bottlenecks of the PCR test was the laborious and time-consuming molecular method for viral genetic material extraction. As a solution, BioEcho developed a novel and rapid multi-well extraction protocol for viral RNA and DNA that reduces the isolation of SARS-CoV-2 nucleic acids to just a few minutes per 96 samples.
SARS-CoV-2 RNA extraction in just 2 minutes
BioEcho?s patent-pending technology is based on a single-step nucleic acid extraction method and differs from the products available on the market, which are established on a silica column that follows the bind-wash-elute principle. The cutting-edge BioEcho technology increases the throughput by reducing the time for viral genetic material extraction procedure to 2 minutes following sample preparation. Speeding up this step more than 20-fold over other extraction technologies leads to thousands of tests on COVID-19 easily achievable per day.
Agile solutions for molecular diagnostics
BioEcho?s pioneering product, EchoLUTION for viral RNA and DNA extraction 48-well or 96-well kit, has been validated by multiple diagnostic laboratories for SARS-CoV-2 detection from nasopharyngeal samples. All could significantly increase their test-throughput up to many thousands per day. BioEcho?s viral nucleic acids extraction products already cover almost 12% COVID-19 PCR tests performed in Germany and estimated 50% in Austria.
BioEcho Life Sciences is a young and innovative company active in the field of Genomic Sample Preparation - the isolation and processing of DNA and RNA. Founded by a team of former Qiagen executives, BioEcho uses their know how to overcome the limitations of common methods in molecular biology and to establish sustainable processes. Their technological solutions were unthinkable until recently. Core technologies include dramatically simplified isolation procedures for nucleic acids in a single step, which form the basis of BioEcho''s portfolio of kits for purification and processing of DNA and RNA. Applying their single-step technologies, BioEcho Life Sciences paves the way for future nucleic acid analyses as well as novel approaches in genomic research and molecular diagnostics.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
BioEcho Life Sciences is a young and innovative company active in the field of Genomic Sample Preparation - the isolation and processing of DNA and RNA. Founded by a team of former Qiagen executives, BioEcho uses their know how to overcome the limitations of common methods in molecular biology and to establish sustainable processes. Their technological solutions were unthinkable until recently. Core technologies include dramatically simplified isolation procedures for nucleic acids in a single step, which form the basis of BioEcho''s portfolio of kits for purification and processing of DNA and RNA. Applying their single-step technologies, BioEcho Life Sciences paves the way for future nucleic acid analyses as well as novel approaches in genomic research and molecular diagnostics.
Datum: 07.12.2020 - 09:31 Uhr
Sprache: Deutsch
News-ID 1562889
Anzahl Zeichen: 2633
contact information:
Contact person:
Town:
Köln
Phone:
Kategorie:
Handcrafts
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 440 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Speeding up COVID-19 PCR-test diagnostics
"
steht unter der journalistisch-redaktionellen Verantwortung von
BioEcho Life Sciences GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
